PFE

Pfizer
D

PFE

Arincen59/100B

Pfizer total debt 1985–2026

Pfizer's total debt was 62.67B USD on 27 September 2026, up 1.6% on a year before. At the end of fiscal year 2025 it was 67.42B USD.

Last updated 3 Nov 2026 · Next report 2 Feb 2027

Total debt

Growth

Fiscal yearPeriod endingTotal debtGrowthCash and short-term investmentsNet cashDebt to equity
Latest quarter27 Sept 202662.67B+1.55%14.27B-48.40B0.70
FY202531 Dec 202567.42B+0.63%13.60B-53.82B0.78
FY202431 Dec 202466.99B-5.44%20.48B-46.52B0.76
FY202331 Dec 202370.85B+103.23%12.69B-58.16B0.80
FY202231 Dec 202234.86B-5.78%22.73B-12.13B0.36
FY202131 Dec 202137.00B-3.33%31.07B-5.93B0.48
FY202031 Dec 202038.27B-24.72%12.22B-26.05B0.61
FY201931 Dec 201950.84B+21.79%9.65B-41.19B0.81
FY201831 Dec 201841.75B-2.02%18.83B-22.91B0.66
FY201731 Dec 201742.61B+3.76%19.99B-22.61B0.60
FY201631 Dec 201641.06B+5.56%17.85B-23.21B0.69
FY201531 Dec 201538.90B+6.04%23.29B-15.61B0.60
FY201431 Dec 201436.68B+0.53%36.12B-560.00M0.51
FY201331 Dec 201336.49B-2.59%32.41B-4.08B0.48
FY201231 Dec 201237.46B-3.81%32.40B-5.06B0.46
FY201131 Dec 201138.94B-11.56%26.40B-12.54B0.47
FY201031 Dec 201044.03B-9.51%28.01B-16.02B0.50
FY200931 Dec 200948.66B+181.56%25.97B-22.69B0.54
FY200831 Dec 200817.28B+31.54%23.73B6.45B0.30
FY200731 Dec 200713.14B+64.65%25.48B12.34B0.20
FY200631 Dec 20067.98B-55.51%27.71B19.73B0.11
FY200531 Dec 200517.94B-3.28%22.23B4.29B0.27
FY200431 Dec 200418.55B+27.26%19.89B1.35B0.27
FY200331 Dec 200314.57B+23.41%11.95B-2.62B0.22
FY200231 Dec 200211.81B+33.10%12.55B742.00M0.59
FY200131 Dec 20018.87B+63.93%8.62B-257.00M0.48
FY200031 Dec 20005.41B-23.48%6.86B1.45B0.34
FY199931 Dec 19997.07B+117.23%6.06B-1.01B0.80
FY199831 Dec 19983.26B+9.41%1.55B-1.70B0.37
FY199731 Dec 19972.98B+1.85%877.00M-2.10B0.38
FY199631 Dec 19962.92B+1.87%1.15B-1.77B0.42
FY199531 Dec 19952.87B+1.57%403.30M-2.47B0.52
FY199431 Dec 19942.82B+61.45%1.46B-1.37B0.65
FY199331 Dec 19931.75B-4.07%729.40M-1.02B0.45
FY199231 Dec 19921.82B-12.65%1.26B-566.50M0.39
FY199131 Dec 19912.09B+23.34%1.32B-770.10M0.42
FY199031 Dec 19901.69B-1.42%870.30M-822.30M0.33
FY198931 Dec 19891.72B+43.72%825.40M-891.50M0.38
FY198831 Dec 19881.19B+23.95%807.50M-387.10M0.28
FY198731 Dec 1987963.80M+73.13%1.03B67.30M0.25
FY198631 Dec 1986556.70M+9.29%398.60M-158.10M0.16
FY198531 Dec 1985509.40M—412.60M-96.80M0.17

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Total debt counts commercial paper, term debt and lease liabilities.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Free cash flow,Stock buybacks,Balance sheet

Common questions about Pfizer's debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.